National Institutes of Health

We hold worldwide exclusive ABP-110 (GPC3/CD3) under a patent license granted by the National Cancer Institute, or NCI, a division of the NIH, effective as of August 1, 2017. Our field of use is to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing liver cancer using a particular moiety for targeting GPC3.